Gender and uveitis in patients with multiple sclerosis. by Gordon, Lynn K & Goldstein, Debra A
UCLA
UCLA Previously Published Works
Title
Gender and uveitis in patients with multiple sclerosis.
Permalink
https://escholarship.org/uc/item/50j2b2f1
Authors
Gordon, Lynn K
Goldstein, Debra A
Publication Date
2014
DOI
10.1155/2014/565262
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Review Article
Gender and Uveitis in Patients with Multiple Sclerosis
Lynn K. Gordon1 and Debra A. Goldstein2
1 Department of Ophthalmology, Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
2Department of Ophthalmology, Northwestern Feinberg School of Medicine, Chicago, IL 60613, USA
Correspondence should be addressed to Lynn K. Gordon; lgordon@ucla.edu
Received 4 October 2013; Accepted 30 March 2014; Published 7 May 2014
Academic Editor: Janet L. Davis
Copyright © 2014 L. K. Gordon and D. A. Goldstein. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Multiple sclerosis (MS), a demyelinating disease of the central nervous system, is more commonly seen in women. It has been
associated with both anterior and intermediate uveitis as well as retinal vasculitis. Ocular inflammation may develop concurrent
with, prior to, or after the development of neurologic signs and symptoms. Patients with MS have an approximately 1% chance of
developing intraocular inflammation. Patients with intermediate uveitis have an 8–12% risk of being diagnosed withMS.This risk is
higher in females and in those with bilateral disease.This should be kept inmind when evaluating patients with uveitis, particularly
in those patients for whom TNF inhibitor therapy is being considered, as these agents may worsen demyelinating disease.
1. Introduction
Multiple sclerosis (MS), a chronic and episodic demyelinating
disease of the central nervous system, affects many aspects of
vision and ocular health, from afferent to efferent pathways.
Ocular signs and symptoms associated with MS range from
optic neuritis, the most commonly associated ophthalmo-
logic disease, which occurs in nearly 50% of MS patients, to
internuclear ophthalmoplegia, associated with demyelinating
lesions of the medial longitudinal fasciculus, and to various
types of debilitating nystagmus and, less commonly, ocular
inflammatory disease [1–4]. Disability secondary to visual
symptoms is an important cause of morbidity among patients
with MS [5]. A large sampling of self-reported data from
almost 9000 North American patients with MS revealed that
nearly 16% of patients reported a visual comorbidity, most
occurring after the diagnosis of MS was made [5]. Uveitis
was identified by 3% of these individuals as responsible
for significant disease morbidity. In this paper we highlight
gender differences in MS and review the data regarding MS-
associated uveitis.
2. Gender Differences in Prevalence/Incidence
Autoimmune diseases are a significant cause of morbidity
and mortality, which disproportionately affect young and
middle-aged women [6]. For MS, the female to male ratio is
estimated to be approximately 3.5 : 1, and the ratio of affected
women to affected men has actually increased over the past
several decades [7].Theprevalence is estimated to be around 1
per 100,000 individuals. Although themean age for diagnosis
of MS is around 37, the typical age of onset ranges from
the early 20s to the mid 40s. However, MS can also occur
in children and in older adults; it is just less commonly
diagnosed at the extremes of life.
There are geographic differences in disease onset, typi-
callywith higher incidence in countries further away from the
equator and a lower incidence in Asia, possibly implicating
environmental factors or infectious agents in disease patho-
genesis [8]. However, there are exceptions to this observation
and this generalization is not completely valid. Some popu-
lations are at high risk in countries close to the equator and
others are at low risk in certain northern countries [9]. The
risk for disease in these countries may reflect other genetic,
epigenetic, or noninfectious environmental factors.
In addition to differences in rates of development of MS
between men and women, there are differences between the
sexes in age at development of the disease and, possibly, in
disease course. One large series reported that MS presented,
on average, two years later in men than women (31.2 years
versus 29.3 years) [10]. As well, there is evidence from
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some series that males are more likely to develop primary-
progressive MS, although this has not been borne out by a
large meta-analysis [11].
Genetic susceptibility factors also play an important role,
with an increased concordance of disease among monozy-
gotic twins as compared to dizygotic twins, as well as an
increased risk for MS among first-degree relatives of patients
with the disease. Risk loci in the human leukocyte antigen
(HLA) family of molecules including HLA-DRB1 have been
implicated in disease susceptibility [7, 12, 13]. Large genome
wide association studies (GWAS) demonstrated additional
complex genetic candidates for disease susceptibility; these
candidates typically involve genes in immunologic pathways
including T-cell differentiation [7].
3. Clinical Manifestations of
Inflammatory Ocular Disease
The clinical manifestations of intraocular inflammation in
MS include chronic anterior uveitis, intermediate uveitis,
and retinal vasculitis [14–18]. In addition to vasculitis and
ischemia, granulomatous retinal periphlebitis was found in
4 cases (7 eyes) and focal lymphocytic or granulomatous
retinitis was present in 3 cases (5 eyes) of 47 autopsy cases of
multiple sclerosis studied pathologically [19]. Complications
of inflammation include cataract, elevation in intraocular
pressure, hypotony, retinal ischemia, and retinal neovascu-
larization. In one retrospective study, the authors described
16 patients seen in a uveitis service who carried a diagnosis of
MS [14]. They observed anterior uveitis in about 30% of eyes
and intermediate uveitis and posterior uveitis each in about
20% of eyes.Three of the patients were not known to haveMS
at the time of their ocular disease onset. In a different study,
3.1% of 1916 uveitis patients seen in a tertiary care clinic had a
diagnosis of MS [20]. In this study anterior uveitis accounted
for 10% and intermediate uveitis comprised 78% of the uveitis
seen in patients with MS; posterior and panuveitis were each
seen in a single patient. Of those with both MS and uveitis,
74.6% were female, highlighting the gender disparity of the
underlying autoimmune disease.
Another study of 1254 patients with uveitis revealed 16
with a concomitant diagnosis of MS, for a prevalence of 1.3%;
the majority of these patients had bilateral disease [21]. Nine
of these patients had diagnoses of MS that preceded onset
of uveitis, three patients had concurrent diagnoses, and four
patients developed uveitis prior to the diagnosis of MS. 88%
of these patients were female. The mean age for the diagnosis
of uveitis was 37.2 and mean age for diagnosis of MS was 35.5
years. Almost half of these patients also had optic neuritis.
Granulomatous anterior uveitis was present in 56%, cataract
in 38%, intermediate uveitis in 81%, and retinal vasculitis in
56%. Cystoid macular edema was present in about a third of
affected patients. Although uveitis is the most common cause
of macular edema in MS patients, it must be recognized that
fingolimod, an oral agent FDA approved for MS treatment,
is itself associated with development in macular edema in
approximately 0.05% of patients [22].
5970 patients with chronic anterior uveitis (CAA) from
a different tertiary care uveitis referral center who were
evaluated over a period of three decades were analyzed
for underlying systemic disease [23]. Multiple sclerosis was
present in 30 patients (1.6%). Notably, the percentage of
patients with MS increased each decade and was associated
with 2.36% of all new patients with CAA evaluated between
1995 and 2004. In a cross-sectional study of uveitis patients
seen in Vienna between 1995 and 2009, the prevalence of MS
was 0.9% [24]. Of the 25 cases of uveitis withMS described in
that study, 19 were intermediate, 4 were anterior, and 2 were
posterior. The mean age of these patients was 35.9 years but
the gender distribution was not reported.
Uveitis may be associated with multiple types of neuro-
logical disease. A retrospective review of all patients seen in
a tertiary care center with a diagnosis of uveitis identified
115 patients with an underlying neurological disease [25].
Fourteen of these patients, or 1% of the total number of
patients seen in the referral center over the course of fifteen
years, were diagnosed as having MS. Half of these patients
(50%) carried a diagnosis of pars planitis and 29% had
chronic granulomatous uveitis. Intermediate uveitis typically
affects patients in the younger years, ranging from age 5 to
30, and does not typically have associations with either race
or gender [26]. Bilateral disease is seen in at least 80%, and
complications such as cataract, glaucoma, or cystoid macular
edema are common [27].
4. What Is the Risk for Uveitis If
MS Is Diagnosed?
Multiple groups have investigated the frequency of uveitis in
patients with multiple sclerosis but the estimates vary widely
from 0.4% to 28.5% depending on the study [28]. One study
prospectively evaluated 50 MS patients, 61.8% of whom were
female, with a complete eye examination in order to identify
concomitant inflammatory eye disease [29]. None of the
patients had a history of eye disease, including optic neuritis.
Nine of the patients (18%), 4 female and 5 male, had retinal
vascular changes, either venous sheathing or focal cuffing,
often with fluorescein angiographic evidence of leakage and
inflammation, without overt cells. Interestingly, a similar
study was performed in Egypt in which 75 patients with MS
were prospectively evaluated with a full ophthalmological
examination [30].This study differs frommost studies onMS
in that there was not a striking female preponderance (34
males, 41 females), although it is not clear if this reflected
the gender distribution of patients in this country with MS.
In this cohort, seven patients were diagnosed as having
intermediate uveitis and, in contrast to other studies, five of
the seven were male and all of the males were young, with
a mean age of 20. A separate study performed in Croatia
identified intermediate uveitis in 28.5% of a total of 42
patients withMS [31].This is a very high prevalence of uveitis,
higher than other studies, and it would be interesting to
understand more about this patient population to determine
why their risk for uveitis is so high.
A population based study of uveitis prevalence in 4300
patients in the Lyon Multiple Sclerosis cohort was per-
formed using self-reporting of uveitis. The records of 31
identified patients were extracted and evaluated for uveitis
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classification, gender, and timing of MS onset. Three patients
who either had Fuchs disease or HLA B27 associated disease
were excluded from additional analysis. In the final cohort,
28 individuals were identified, 0.65% of the total number of
MSpatients.Women comprised 68%of the total patients with
uveitis. In 46% of the patients, uveitis preceded the onset
of MS. In this series 36% of patients had posterior uveitis
whereas intermediate uveitis only was diagnosed in 7% of the
patients [28]. Similarly, another review of 1098 patients from
an MS clinic revealed a 1% prevalence of uveitis [32].
In a large population based study in the Northern Cali-
fornia Kaiser PermanenteMedical Care Program, a computer
search of records of more than 5,000 patients with MS
and age-matched controls was evaluated for prevalence of
uveitis, among other autoimmune diseases [33]. Uveitis was
diagnosed in 1.3% of patients withMS as compared to 0.6% of
controls. Additional information about the demographics or
type of uveitis is not available. In this series, uveitis preceded
the diagnosis of MS in only 1% of patients. The population
based studies on the prevalence of uveitis in MS are large and
confirm that 0.65–1.3% of patients with MS will have uveitis.
What is less clear is the timing of onset of uveitis relative to
MS, with uveitis preceding MS diagnosis in anywhere from
1 to 46% of patients. These reports are somewhat limited by
the quality of the available data but underscore the need to
consider uveitis in patients with MS.
5. What Is the Risk of MS If Intermediate
Uveitis (Pars Planitis) Is Diagnosed?
The term intermediate uveitis is a general one that describes
uveitis in which the inflammatory cells are primarily located
in the vitreous cavity. Pars planitis refers to a specific subset
of idiopathic intermediate uveitis in which there is snowball
or snowbank formation and no underlying systemic disease
responsible for the inflammation [34]. Older studies did not
excludeMSpatients from the diagnosis of pars planitis, and in
this section we therefore report series on intermediate uveitis
and on pars planitis. The experience of a large tertiary care
center with patients who carry a diagnosis of intermediate
uveitis was published in 1993 [27]. In this retrospective study,
7% of patients with intermediate uveitis had MS. Another
large series of 53 patients with pars planitis was reported in
1999 [35]. The mean age at diagnosis was 26 years with a
range of 5 to 50 years. There were 20 males and 33 females.
General medical or neurological data was available for 37
of the patients. Six were diagnosed with MS (11% of all
intermediate uveitis patients), three prior to onset of uveitis.
The patients with MS and pars planitis tended to be female
(83%) and older (mean age of 36) and were also more likely
to have vascular sheathing on examination. Another study of
patients evaluated at a tertiary care uveitis center identified
intermediate uveitis in 22.9% of patients (𝑛 = 438), and 10.3%
of these patients had MS [20]. In another prospective clinical
study of 21 patients with pars planitis, 47.6% demonstrated
demyelinating lesions on MRI and 33.3% were diagnosed
with definitive MS. Those patients diagnosed with MS were
more likely to be older than the age of 25 [36]. This series
reports the highest association with MS in patients with
intermediate uveitis.
A population based study was performed in Olmsted,
County, Minnesota, looking at all patients with a diagnosis
of pars planitis who had been evaluated over a 20-year time
period [37]. 25 patients with pars planitis who had sufficient
medical records, provided authorization for the study, and
did not have sarcoidosis or Behcet disease were identified.
With longitudinal followup for a mean of 14.3 years, MS was
diagnosed in 3 of the patients, for a rate of 12%.
Not surprisingly, there is geographic variation in rates
of MS diagnosed in patients with intermediate uveitis. A
recent study of 87 intermediate uveitis patients in a referral
service in Tunisia revealed a lower percentage of patients
with underlying MS (2.3%) and a higher association with
sarcoidosis (9.2%) [38].
Genetic testing for risk factors in patients with intermedi-
ate uveitis reveals association with the IL2RA rs2104286 gene
polymorphism [39]. Interestingly this same polymorphism is
observed in MS and other autoimmune diseases.
Overall, in the majority of studies, 8–12% of patients
with intermediate uveitis carry a diagnosis of or will develop
MS. Additional risk factors for this diagnosis include female
gender and bilateral disease. Although there is a gender
disparity in rates of disease, these likely reflect the underlying
increase in MS in females.
6. Possible Explanations for Gender
Differences in MS
The gender differences in rates of MS are not understood,
but there are many hypotheses with supporting data that
suggest potential mechanisms [40]. There is a large body
of literature that explores this topic, and only several of
the leading hypotheses are presented here. One possibility
is that these differences are mediated by epigenetic DNA
modification by either hormonal or environmental stimuli
[41]. Other studies implicate the X chromosome in disease
susceptibility. For example, in the rodent MS model of
experimental autoimmune encephalitis (EAE), having two X
chromosomes increases disease susceptibility for unknown
reasons [42]. Interestingly, in studies where the EAE disease
was transferred from affected mice using purified T lympho-
cytes, T cells from female donors were more successful in
creating disease in the recipient than were T cells from male
donors, thus suggesting that there must be sexual differences
in activation of the immune response [43]. There was also
increased disease in female recipients in contrast to male
recipients, implicating increased effector activation that is
also determined by gender [44].
Hormonal differences between females and males may
also impact disease severity and progression. Pregnancy
is well documented to be associated with a decrease in
MS relapses [7]. During pregnancy, the high expression of
estriol, which is not measurable outside of pregnancy, may be
associated with a milder course [26]. Phase II clinical trials
are currently ongoing using exogenous estriol as a potential
therapy inMS [45, 46]. VitaminD has also been postulated to
play a role in disease pathogenesis. Patients withMS typically
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have lower levels of vitamin D, and some studies report lower
levels of vitaminD in females in comparison tomales [47]. In
EAE experiments, increasing vitamin D in the diet has been
shown to ameliorate the disease [26].
7. Conclusion
These studies suggest that up to 3% of all patients evaluated
in uveitis clinics also carry a diagnosis of MS. The uveitis
observed in these patients is often bilateral. Intermediate
uveitis is the most common, followed by anterior uveitis,
which may be characterized by a granulomatous appearance.
Retinal vascular changes in the absence of symptoms are
seen in a significant percentage of patients. Patients who
have known MS carry an approximately 1% risk of devel-
oping clinical intraocular inflammatory disease. Conversely,
patients with intermediate uveitis are atmoderate risk forMS,
around 8–12%.The risk is higher in females and in those with
bilateral disease.Therefore, these patients should be routinely
questioned regarding transient (lasting several weeks) neu-
rologic symptoms that might otherwise be ignored by the
patient. Patients with uveitis and MS are more likely to be
female, in concordance with the gender predisposition for
MS. Importantly some cases of uveitis occur prior to the diag-
nosis of MS, and in these patients one must be particularly
careful to be alert to the possible diagnosis, in particular if
biologic immune modulators are contemplated for therapy,
as exposure to TNF-alpha inhibitors heightens the risk for
demyelinating lesions [48].
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